Exenatide
Renal Failure
Rigshospitalet, Denmarkprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Renal Failure cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NORMAL HUMAN SERUM ALBUMIN Anna Cruceta | Phase 4 | BBB |
Midodrine Anna Cruceta | Phase 4 | BB |
DEXAMETHASONE Augusta University | Phase 3 | BB |
Envarsus Product University of Alberta | Phase 4 | BB |
Empagliflozin University Hospital, Basel, Switzerland | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Exenatide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →